$6.82 +0.20 (+3.02%) (As of 02:12 PM ET) 52-Week Range $2.09 ▼ $14.84 Price Target $18.80 Clinical-state biopharmaceutical company Altimmune Inc. NASDAQ: ALT focuses on developing peptide-based therapeutics for obesity and chronic liver diseases, including non-alcoholic steatohepatitis (NASH). Their top candidate is a GLP-1/glucagon agonist called pemvidutide. It’s a dual receptor agonist like Eli Lilly &…
$27.89 -0.16 (-0.57%) (As of 02:28 PM ET) 52-Week Range $25.20 ▼ $37.80 Dividend Yield 6.02% Price Target $35.54 Pharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly…
LLY Eli Lilly and Company $918.00 +3.43 (+0.38%) (As of 07/8/2024 ET) 52-Week Range $434.34 ▼ $928.60 Dividend Yield 0.57% P/E Ratio 135.20 Price Target $816.78 Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but…